Journal
BIOSENSORS-BASEL
Volume 12, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/bios12090728
Keywords
lateral flow immunoassay; biosensors; COVID-19; SARS-CoV-2; diagnosis; antibodies
Funding
- PRODEP (Programa para el Desarrollo Profesional Docente en Educacion Superior)
- Universidad Autonoma del Estado de Hidalgo and Consejo Nacional de Ciencia y Tecnologia (CONACyT)
Ask authors/readers for more resources
This review summarizes the advantages, limitations, and evolution of lateral flow immunoassays (LFIA) during the SARS-CoV-2 pandemic and the challenges of improving these diagnostic devices.
SARS-CoV-2 is an emerging infectious disease of zoonotic origin that caused the coronavirus disease in late 2019 and triggered a pandemic that has severely affected human health and caused millions of deaths. Early and massive diagnosis of SARS-CoV-2 infected patients is the key to preventing the spread of the virus and controlling the outbreak. Lateral flow immunoassays (LFIA) are the simplest biosensors. These devices are clinical diagnostic tools that can detect various analytes, including viruses and antibodies, with high sensitivity and specificity. This review summarizes the advantages, limitations, and evolution of LFIA during the SARS-CoV-2 pandemic and the challenges of improving these diagnostic devices.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
